Studies for development of novel quinazolinones: new biomarker for EGFR.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Spectrochimica Acta Part A - Molecular and Biomolecular Spectroscopy

• Publication date

  2015-05-15

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.saa.2015.01.069PMID 25766241
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Vibrational spectroscopic (FT-IR and FT-Raman) studies, HOMO-LUMO, NBO analysis and MEP of 6-methyl-1-({[(2E)-2-methyl-3-phenyl-prop-2-en-1-yl]oxy}methyl)-1,2,3,4-tetra-hydroquinazoline-2,4-dione, a potential chemotherapeutic agent, using density functional methods.

  2015cited by this paper
• Synthesis and biological evaluation of newly designed phosphonate based bone-seeking agent.

  2013cited by this paper
• Design and Docking Studies of [Diethylenetriaminepentaacetic Acid–(Amino Acid)2] with Acetylcholine Receptor as a Molecular Imaging Agent for Single-Photon Emission Computed Tomographic Application

  2012cited by this paper
• Design and synthesis of 4,6-substituted-(diaphenylamino)quinazolines as potent EGFR inhibitors with antitumor activity.

  2012cited by this paper
• Design, synthesis and biological evaluation of novel quinazoline derivatives as potential antitumor agents: molecular docking study.

  2010cited by this paper
• Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer.

  2010cited by this paper
• Quantitative structure-activity relationship analysis of 4(3H)-quinazolone derivatives as tyrosine kinase inhibitors by multiple linear regression.

  2010cited by this paper
• Disubstituted 4(3H) Quinazolones: A Novel Class of Antitumor Agents

  2009cited by this paper
• Synthesis and characterization of rhenium and technetium-99m tricarbonyl complexes bearing the 4-[3-bromophenyl]quinazoline moiety as a biomarker for EGFR-TK imaging.

  2009cited by this paper
• Sensitised near-IR lanthanide luminescence exploiting anthraquinone-derived chromophores: syntheses and spectroscopic properties.

  2009cited by this paper
• Anti-epidermal growth factor receptor (anti-EGFR) antibody conjugated fluorescent nanoparticles probe for breast cancer imaging.

  2009cited by this paper
• 99mTc‐DTPA‐Amino Acids Conjugate as Specific SPECT Pharmaceuticals for Tumor Imaging

  2009cited by this paper
• Effect of a Novel Series of Benzothiazolo‐Quinazolones on Epidermal Growth Factor Receptor (EGFR) and Biological Evaluations

  2008cited by this paper
• Synthesis, characterization and biological activity of Schiff base analogues of indole-3-carboxaldehyde.

  2008cited by this paper
• Design, synthesis, and in vitro antitumor activity of new 1,4-diarylimidazole-2-ones and their 2-thione analogues.

  2008cited by this paper
• Synthesis and structure-activity relationships of novel 1-arylmethyl-3-aryl-1H-pyrazole-5-carbohydrazide hydrazone derivatives as potential agents against A549 lung cancer cells.

  2008cited by this paper
• Evaluation of radiolabeled ML04, a putative irreversible inhibitor of epidermal growth factor receptor, as a bioprobe for PET imaging of EGFR-overexpressing tumors.

  2007cited by this paper
• Synthesis and biological properties of 4-(3H)-quinazolone derivatives.

  2007cited by this paper
• Lapatinib: A Novel Dual Tyrosine Kinase Inhibitor with Activity in Solid Tumors

  2006cited by this paper
• Synthesis and pharmacological study of novel pyrido-quinazolone analogues as anti-fungal, antibacterial, and anticancer agents.

  2006cited by this paper
• High-affinity epidermal growth factor receptor (EGFR) irreversible inhibitors with diminished chemical reactivities as positron emission tomography (PET)-imaging agent candidates of EGFR overexpressing tumors.

  2005cited by this paper
• Gefitinib — a novel targeted approach to treating cancer

  2004cited by this paper
• The human genome project and the discovery of genetic determinants of cancer susceptibility.

  2004cited by this paper
• Syntheses and EGFR kinase inhibitory activity of 6-substituted-4-anilino [1,7] and [1,8] naphthyridine-3-carbonitriles.

  2004cited by this paper
• Gefitinib, a novel, orally administered agent for the treatment of cancer

  2004cited by this paper
• Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.

  2003cited by this paper
• The ErbB receptors and their role in cancer progression.

  2003cited by this paper
• ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy.

  2002cited by this paper
• Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains.

  2002cited by this paper
• Smart drugs: tyrosine kinase inhibitors in cancer therapy.

  2002cited by this paper
• Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor*

  2002cited by this paper
• The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities.

  2001cited by this paper
• The 4-anilinoquinazoline class of inhibitors of the erbB family of receptor tyrosine kinases.

  2001cited by this paper
• Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.

  2001cited by this paper
• Untangling the ErbB signalling network

  2001cited by this paper
• Tyrosine kinase inhibitors: From rational design to clinical trials

  2001cited by this paper
• EGF mutant receptor vIII as a molecular target in cancer therapy.

  2001cited by this paper
• Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer.

  2001cited by this paper
• The ErbB receptor tyrosine family as signal integrators.

  2001cited by this paper
• Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors.

  2000cited by this paper
• The EGF receptor family as targets for cancer therapy

  2000cited by this paper
• Co‐expression of epidermal growth factor receptor and transforming growth factor‐α predicts worse prognosis in breast‐cancer patients

  2000cited by this paper
• Role of conformational alteration in the epidermal growth factor receptor (EGFR) function.

  2000cited by this paper
• The rationale and strategy used to develop a series of highly potent, irreversible, inhibitors of the epidermal growth factor receptor family of tyrosine kinases.

  1999cited by this paper
• Genistein analogues: effects on epidermal growth factor receptor tyrosine kinase and on stress-activated pathways.

  1997cited by this paper
• In vivo pharmacology and anti-tumour evaluation of the tyrphostin tyrosine kinase inhibitor RG13022.

  1996cited by this paper
• Inhibition of the epidermal growth factor receptor tyrosine kinase by PD153035 in human A431 tumors in athymic nude mice

  1995cited by this paper
• A specific inhibitor of the epidermal growth factor receptor tyrosine kinase.

  1994cited by this paper
• Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells

  1984cited by this paper
• Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences

  1984cited by this paper

• New quinazolone derivatives: Synthesis, Spectroscopic, X-ray, DFT calculation and Biological activity studies

  2023cites this paper
• Bialorastins A-F, highly oxygenated and polycyclic andrastin-type meroterpenoids with proangiogenic activity from the deep-sea cold-seep-derived fungus Penicillium bialowiezense CS-283.

  2023cites this paper
• Design, synthesis, biological evaluation, and molecular docking of novel quinazolinone EGFR inhibitors as targeted anticancer agents

  2022cites this paper
• Design, synthesis and Molecular modeling study of certain EGFRinhibitors with a quinazolinone scaffold as anti-hepatocellular carcinoma and Radio-sensitizers.

  2022cites this paper
• Rational design-aided discovery of novel 1,2,4-oxadiazole derivatives as potential EGFR inhibitors.

  2021cites this paper
• Design, synthesis and in vitro biological evaluation of quinazolinone derivatives as EGFR inhibitors for antitumor treatment

  2020cites this paper
• 3D-QSAR studies on quinazoline derivatives as EGFR-T790M inhibitors by Comparative Molecular Field Analysis (CoMFA)

  2016cites this paper